Drug Profile


Alternative Names: ABmFPP; ABPP; BRM; NSC 149027; Remisar; U 54461; U 54461S; U 56499

Latest Information Update: 02 May 2008

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Pharmacia Corporation; Yakult Honsha
  • Class Antineoplastics; Pyrimidinones; Small molecules
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Bladder cancer; Herpes simplex virus infections; Lymphoma

Most Recent Events

  • 09 Apr 2002 No development reported - Phase-III for Lymphoma in USA (PO)
  • 09 Apr 2002 No development reported - Phase-II for Herpes simplex virus infections in Japan (Topical)
  • 09 Apr 2002 No development reported - Phase-III for Herpes simplex virus infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top